Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab

Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue and E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;
Ruby Meredith
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sui Shen
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Bunch
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Straughn
2Gynecology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julien Torgue
3AREVA Med, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Banaga
3AREVA Med, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 55 no. supplement 1 638

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 5, 2014.

Copyright & Usage 
© 2014

Author Information

  1. Ruby Meredith1,
  2. Sui Shen1,
  3. Patty Bunch1,
  4. Michael Straughn2,
  5. Julien Torgue3 and
  6. E. Banaga3
  1. 1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  2. 2Gynecology, University of Alabama Medical, Birmingham, AL
  3. 3AREVA Med, Bethesda, MD

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Jan 20151100
Feb 2015300
Mar 2015100
Apr 2015100
May 2015200
Jun 2015200
Aug 2015800
Sep 20151500
Oct 2015300
Nov 2015100
Dec 2015600
Jan 2016400
Feb 2016100
Apr 2016200
Jun 2016200
Jul 20161100
Aug 2016100
Sep 2016400
Oct 2016600
Nov 2016200
Dec 2016300
Jan 2017800
Feb 2017500
Mar 2017800
Apr 2017300
May 2017800
Jun 2017400
Jul 2017400
Aug 2017400
Sep 2017400
Oct 2017300
Nov 2017100
Dec 2017400
Jan 2018200
Mar 2018300
Apr 2018200
May 20181300
Jun 2018100
Jul 2018200
Aug 2018200
Sep 2018100
Oct 2018300
Nov 2018400
Dec 2018100
Feb 2019300
Apr 2019100
Jul 2019100
Oct 2019100
Nov 2019700
Jan 2020200
Feb 2020800
Mar 20201600
Apr 2020800
Jul 2020300
Aug 2020700
Sep 20202400
Oct 20201300
Nov 20201300
Dec 20201100
Jan 2021500
Feb 20211500
Mar 20211000
Apr 20211000
May 2021700
Jun 2021200
Jul 20211200
Aug 20213300
Sep 20211300
Oct 20213000
Nov 20216700
Dec 20214300
Jan 20226600
Feb 20222100
Mar 20221400
Apr 2022500
May 20222700
Jun 2022500
Jul 2022100
Aug 2022400
Sep 2022300
Oct 2022600
Nov 2022200
Dec 2022400
Jan 2023100
Feb 2023100
Mar 2023300
Apr 2023100
May 2023400
Jun 2023400
Jul 2023200
Aug 2023500
Sep 20231000
Oct 2023600
Nov 2023300
Dec 2023400
Jan 2024400
Feb 2024500
Mar 2024400
Apr 2024400
May 2024400
Jun 2024800
Jul 20241100
Aug 20241200
Sep 2024900
Oct 2024400
Nov 2024800
Dec 2024600
Jan 2025200
Feb 2025200
Mar 2025100
Apr 20251500
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 55, Issue supplement 1
May 2014
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue, E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue, E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Lipotecan acts synergistically in combination with 188Re-liposome in hepatocellular carcinoma xenograft mouse model
  • 177mLu impurity: Practical aspects of 177mLu hospital waste management
  • Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer. Preclinical evaluation of kallikrein related peptidase 2 targeting
Show more Oncology: Basic, Translational & Therapy

Radiopharmaceutical Therapy: Radioimmunotherapy

  • Treatment of bladder cancer with Bi-213-anti-EGFR-MAb - A pilot study
  • Strong anti-tumor effect of 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
Show more Radiopharmaceutical Therapy: Radioimmunotherapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire